New Three-Drug attack on tough head & neck cancer
NCT ID NCT07320963
Summary
This study is testing a combination of three drugs (chidamide, toripalimab, and anlotinib) for people with advanced nasopharyngeal cancer that has come back or spread after at least one prior treatment. The main goals are to find the safest dose of chidamide in this combo and to see how well the treatment shrinks tumors. It will enroll about 52 adults whose cancer has progressed despite standard therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.